Lunit Inc.
6th floor, 175 Yeoksam-ro
Gangnam-gu
Seoul
South Korea
Website: https://www.medeortherapeutics.com/
Email: contact@lunit.io
About Lunit Inc.
Lunit Inc., a member company of the K-ICT Born2Global Centre, has developed a deep learning-based technology for analyzing medical images that dramatically lowers the rate of misdiagnosis.
YEAR FOUNDED:
August 24, 2013
LEADERSHIP:
Founders: Anthony Paek, Jungin Lee, Minhong Jang, KyungHyun Paeng, Sunggyun Park, and Donggeun Yoo
Founder and CEO: Anthony Paek
Founder and CPO: Jungin Lee
Founder and COO: Minhong Jang
CMO: Beomseok Brandon Suh
JOBS:
42 articles about Lunit Inc.
-
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
3/18/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announces two commercial deals that signal its expansion in Europe.
-
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured
3/13/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a significant update on its acquisition of Volpara Health Technologies.
-
Lunit Expands AI Medical Imaging Solutions in East & Southeast Asia: Partners with Chung Shan Medical University and Gleneagles Hospital Singapore
3/11/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region.
-
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
2/28/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the presentation of seven studies at the European Congress of Radiology 2024, to be held in Vienna, Austria, from February 28 to March 3.
-
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
2/16/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a groundbreaking study published in the Journal for ImmunoTherapy of Cancer.
-
Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings
1/25/2024
Boston Imaging announced that Samsung has signed a supply contract with Lunit Inc., a leading provider of artificial intelligence powered solutions for cancer diagnostics and therapeutics, to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
-
Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology
1/17/2024
Lunit announced an outstanding performance of its flagship product, Lunit INSIGHT CXR, revealed in a recent groundbreaking study published in the prestigious journal 'Radiology', published by RSNA, with an impact factor of 19.7.
-
Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening
1/16/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a three-year supply contract with Samsung Electronics.
-
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
12/14/2023
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced its proposal to acquire Volpara Health Technologies Ltd., a global leader in AI-enabled software for the early detection and prevention of cancer.
-
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
12/11/2023
BSNSW, a key part of the national BreastScreen Australia Program, is a joint initiative funded by the Commonwealth, state and territory governments, and managed by the Cancer Institute NSW.
-
Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging
11/30/2023
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, partners with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system.
-
Lunit's AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection - published in European Radiology
11/22/2023
Lunit today announced that in a study recently published in European Radiology, Lunit's AI-powered mammography analysis solution, Lunit INSIGHT MMG, has been validated for its effectiveness in standalone breast cancer detection.
-
Lunit Secures $150 Million in Capital Increase
11/15/2023
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the successful completion of a significant paid-in capital increase of $150 million.
-
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT
11/14/2023
Lunit announced that it has received U.S. Food and Drug Administration 510 clearance for its 3D Breast Tomosynthesis AI solution, Lunit INSIGHT DBT.
-
Lunit Expands Reach of its AI-Powered Chest Screening Solution to Global Military Health Institutions
11/9/2023
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced the successful supply of its AI-powered chest screening solution, Lunit INSIGHT CXR, to several key institutions in the Philippines and South Korea military.
-
Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023
11/6/2023
Lunit is set to unveil seven significant abstracts at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place from November 26 to November 30 in Chicago.
-
AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023
11/1/2023
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the presentation of six studies at the upcoming SITC 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California.
-
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
9/27/2023
Lunit announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.
-
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023
8/21/2023
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a groundbreaking study at the 2023 World Conference on Lung Cancer (WCLC 2023), to be held in Singapore on September 9-12.
-
Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis
6/5/2023
Lunit, a leading global provider of AI-powered cancer diagnostic solutions, announced the signing of a supply and license agreement with Capio S:t Göran Hospital, Stockholm, Sweden.